Close
Smartlab Europe
Achema middle east

American Regent Recalls Batch of Calcium Gluconate Injections

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

AstraZeneca-Modella AI Acquisition to Speed Oncology R&D

AstraZeneca has agreed to acquire Boston-based Modella AI as...

Novartis, SciNeuro Brain Shuttle Deal Expands Neuroscience

Novartis has entered into a licensing agreement with SciNeuro...

Bayer-Attralus Diagnostic Tracers Deal Expands Imaging Reach

In order to broaden its portfolio in imaging and...
- Advertisement -

American Regent has initiated a voluntary nationwide recall of a batch of calcium gluconate injections due to the presence of silicone particulates.The recall affects lot number 1,006 of calcium gluconate injection, USP, 10%, 100mL. American Regent has distributed the injections, manufactured by Luitpold Pharmaceuticals, to wholesalers and distributors nationwide.Calcium gluconate is indicated to treat conditions such as hypocalcaemic tetany or hypocalcaemia, to relieve muscle cramping due to black widow spider bites, rickets, osteomalacia, lead colic and magnesium sulphate overdoses.The injection has also been employed to decrease capillary permeability in allergic conditions, non-thrombocytopenic purpura and exudative dermatoses such as dermatitis herpetiformis and for pruritus of eruptions caused by certain drugs.In hyperkalaemia, calcium gluconate may aid in antagonising the cardiac toxicity provided the patient is not receiving digitalis therapy.

Latest stories

Related stories

AstraZeneca-Modella AI Acquisition to Speed Oncology R&D

AstraZeneca has agreed to acquire Boston-based Modella AI as...

Novartis, SciNeuro Brain Shuttle Deal Expands Neuroscience

Novartis has entered into a licensing agreement with SciNeuro...

Bayer-Attralus Diagnostic Tracers Deal Expands Imaging Reach

In order to broaden its portfolio in imaging and...

UK Clinical Trial Regulatory Reforms Aim to Boost Research

A number of regulatory changes have been released by...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »